effects [qlco]
Reduced [qlco]
Dose [qnco]
Hormone replacement therapy [topp]
Endothelial [tisu]
function [phsf]
Intima media thickness [clna]
postmenopausal [tmco]
Women [popg]
Objective [inpr]
Short-term [tmco]
estrogen therapy [topp]
Endothelial [tisu]
function [phsf]
postmenopausal [tmco]
Women [popg]
Report [inpr]
Long-Term Effects [phpr]
Endothelial [tisu]
function [phsf]
Carotid Intima-Media Thickness [clna]
Reduced [qlco]
Dosage [qnco]
Estrogen [horm, phsu, strd]
Maintain [acty]
effects [qlco]
Design [acty]
postmenopausal [tmco]
Women [popg]
Diagnosed [fndg]
Osteoporosis [dsyn]
Women [popg]
prescribed [hlca]
Oral [spco]
Conjugated estrogen [horm, phsu, strd]
mg% [qnco]
medroxyprogesterone acetate 2.5 MG [clnd]
Women [popg]
prescribed [hlca]
Oral supplement [phsu]
Calcium [bacs, elii, phsu]
Control Group [grup]
Take [hlca]
Hormone replacement therapy [topp]
Calcium supplement [food]
Performed [ftcn]
Ultrasound [diap]
Measurement [ftcn]
Endothelial [tisu]
function [phsf]
Brachial Artery [bpoc]
Carotid Intima-Media Thickness [clna]
examinations [hlca]
Scheduled [inpr]
Performed [ftcn]
Pre-Therapy [tmco]
months [tmco]
therapy [ftcn]
therapy [ftcn]
Women [popg]
Hormone replacement therapy [topp]
Group [idcn]
Agree [inpr]
Take [hlca]
Half [qnco]
Dose [qnco]
Oral [spco]
Conjugated estrogen [horm, phsu, strd]
Improvement [cnce]
Flow [npop]
mediated [socb]
Dilatation [topp]
Observed [ftcn]
3 Months [tmco]
Improvement [cnce]
Preserved [lbpr]
months [tmco]
Improvement [cnce]
Observed [ftcn]
Women [popg]
Hormone replacement therapy [topp]
Reduced [qlco]
Dosage [qnco]
Intima media thickness [clna]
Common carotid artery [bpoc]
Control Group [grup]
Increased [qnco]
months [tmco]
Observed [ftcn]
Hormone replacement therapy [topp]
Group [idcn]
Conclusions [idcn]
Half [qnco]
Dose [qnco]
Estrogen [horm, phsu, strd]
Hormone replacement therapy [topp]
Endothelial [tisu]
function [phsf]
PREVENT [phsu]
progression [patf]
Carotid [bpoc]
Intima [tisu]
Media [inpr]
Thickening [fndg]
postmenopausal [tmco]
Women [popg]
